Methotrexate
Small molecule targets DHFR via inhibition
Regulatory milestones approvals, filings & regulatory actions · 8 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | JYLAMVO | — | 2024-10-23 | fda.gov ↗ |
| Label expansion | US (FDA) | METHOTREXATE | — | 2022-03-10 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | METHOTREXATE PRESERVATIVE FREE | — | 1988-04-07 – 2021-03-29 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | METHOTREXATE SODIUM | — | 1988-10-31 – 2020-05-04 | fda.gov ↗ |
| Approved | EU (EMA) | Nordimet | — | 2016-08-18 | europa.eu ↗ |
| Approved | US (FDA) | METHOTREXATE SODIUM | — | 1953-12-07 | fda.gov ↗ |
Trials 696 · started per year
Also used as a comparator or background therapy in 918 trials
Press releases naming this drug 7 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-06-12 | Pfizer | Pfizer Announces Results from XELJANZ® XR (tofacitinib) ORAL Shift Study, The First Phase 3b/4 Study to Evaluate Methotrexate Withdrawal with a JAK Inhibitor pfizer.com ↗ |
| 2019-03-28 | Gilead Sciences | Gilead and Galapagos Announce Filgotinib Meets Primary Endpoint in the Phase 3 FINCH 3 Study in Methotrexate-Naïve Rheumatoid Arthritis Patients gilead.com ↗ |
| 2018-10-24 | Amgen | First Head-to-Head Trial of a TNF Inhibitor Versus Methotrexate Monotherapy in Psoriatic Arthritis Shows ENBREL® (Etanercept) Monotherapy and Combination Therapy Both Superior to Methotrexate amgen.com ↗ |
| 2018-06-05 | AbbVie | Upadacitinib Monotherapy Meets All Primary and Ranked Secondary Endpoints Versus Methotrexate in a Phase 3 Study in Rheumatoid Arthritis abbvie.com ↗ |
| 2015-11-07 | Incyte Corporation | Lilly and Incyte Announce Patients Treated with Baricitinib Demonstrated Significant Improvement in Signs and Symptoms of Rheumatoid Arthritis Compared with Methotrexate incyte.com ↗ |
| 2015-09-29 | Incyte Corporation | Baricitinib Superior to Methotrexate in Reducing Signs and Symptoms in Pivotal Phase 3 Study in Patients with Rheumatoid Arthritis incyte.com ↗ |
| 2013-06-13 | AbbVie | AbbVie Presents First Study Assessing the Role of Predefined Doses of Methotrexate When Used in Combination with HUMIRA® (adalimumab) for Rheumatoid Arthritis abbvie.com ↗ |
Evidence & citations 37 cited values
Every value below carries the sentence it was read from. 1,671 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | methotrexate | “The BAT in this study was identified by the investigator prior to patient randomization among the following treatments currently used in this setting: anti-thymocyte globulin...” NCT02913261 ↗1607“The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG),...” NCT04118556 ↗ “Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive...” NCT02885610 ↗ “The objective of the study is 1. To investigate the efficacy and safety of a high-dose methotrexate-based induction polychemotherapy regimen combined with Rituximab and...” NCT01458730 ↗ “This is an open-label (physician and participant will know the name of the assigned drug), multi-center, non-randomized, drug/drug interaction study of JNJ-38518168 in...” NCT01450982 ↗ “R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2 and 3); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion...” NCT02657785 ↗ “The CNI-based prophylaxis regimen will be identified by the investigator before the subject's enrollment and will consist of the combination of tacrolimus/methotrexate,...” NCT03320642 ↗ “OBJECTIVE: To evaluate the efficacy of 4 cycles of vinblastine, Adriamycin (doxorubicin), methotrexate, and prednisone (VAMP) in patients with favorable-risk Hodgkin lymphoma...” PMID 22735430 ↗ Jun 2012 “R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in...” NCT02836158 ↗ “Four cycles of Induction therapy: Rituximab 375mg/m2 d1; Methotrexate 3.5g/m2 d2;Temozolomide 100mg/m2 d2-6; for patients who reach a CR, PR, or SD, will proceed to autologous...” NCT02399189 ↗ “Patients with a persistently positive interim-PET scan assigned to arm B2 will receive six blocks of the B-ALL protocol (rituximab, methotrexate, ifosfamide, etoposide,...” NCT00554164 ↗ “The investigators conducted a trial to determine whether methotrexate or methotrexate/dactinomycin single-course treatment work well as multiple courses of single methotrexate...” NCT01823315 ↗ “Yisaipu® was introduced only during the active state and was switched to DMARDs, methotrexate(MTX), sulfasalazine(SSZ) and hydroxychloroquine(HCQ), after disease remission (ESR...” NCT03411798 ↗ “During the study, subjects continued to receive 1 or more background non-biologic DMARDs (e.g. methotrexate, leflunomide) at the dose level(s) and regimen(s) administered at...” NCT00124982 ↗ “Standard neoadjuvant chemotherapy for muscle-invasive bladder cancer, typically consisting of cisplatin-based regimens such as MVAC (methotrexate, vinblastine, doxorubicin, and...” NCT07202819 ↗ “Intrathecal chemotherapy will consist of either single-agent cytarabine or methotrexate, or a combination of methotrexate, cytarabine, and hydrocortisone, at appropriate...” NCT04029688 ↗ “OBJECTIVE: To compare the relative bioavailability, safety and tolerability of oral methotrexate (MTX) and subcutaneous (SC) MTX administered via an auto-injector (MTXAI) in...” PMID 24728329 ↗ Apr 2014 “We randomly assigned 958 patients to receive 5 mg or 10 mg of tofacitinib twice daily or methotrexate at a dose that was incrementally increased to 20 mg per week over 8 weeks;...” PMID 24941177 ↗ Jun 2014 “Patients on corticosteroids (plus conventional therapy) will be randomized to receive anakinra (Kineret®), or one of the following: methotrexate, azathioprine, leflunomide,...” NCT01033656 ↗ “Cyclophosphamide (800 mg/m2 IV over 1 hour)+ vincristine (1.5 mg/m2 IV PUSH)+ doxorubicin (40 mg/m2 IV)+ high-dose methotrexate (2,700 mg/m2 IV over 23 hours)+ rituximab (500...” NCT00392990 ↗ “A Multi-cohort, Phase Ⅲ Study of Methotrexate Combined Corticosteroid as First-line Therapy in Chinese Patients With Acute Graft vs. Host Disease After Allogeneic Hematopoietic...” NCT04960644 ↗ “R-HCVAD - Rituximab (375 mg/m2), Cyclophosphamide (300 mg/m2), Mesna (600 mg/m2), Doxorubicin (50 mg/m2), Vincristine (2 mg total), Dexamethasone (40 mg total), Methotrexate...” NCT01854372 ↗ “Patients who receive standard-therapy (Sulphasalazine, Methotrexate, Leflunomide) are treated with common dosages of these drugs that are deduced from the common treatment of...” NCT00244179 ↗ “Used drugs are rituximab,cyclophosphamide, prednisone, dexamethasone, vincristine, methotrexate, iphosphamide, teniposide, etoposide, dexamethasone, cytarabine,adriamycin,...” NCT01290120 ↗ “csDMARDs may include one or two of the following: methotrexate (MTX), hydroxychloroquine or chloroquine, sulfasalazine, and/or leflunomide (combination of leflunomide and MTX...” NCT02873936 ↗ “continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, oral-ly), according to a 2-by-2 factorial design stratified on the initial induction...” NCT00599937 ↗ “The product FBL-MTX consists of Methotrexate (MTX) encapsulating liposomes functionalized with a folate peptide (SP-DS3), which targets activated macrophages of rheumatoid...” NCT05117593 ↗ “Agents for intrathecal (IT) chemotherapy, central nervous system (CNS)-1/2: IT methotrexate chemotherapy, or CNS-3: triple intrathecal (ITT) methotrexate, hydrocortisone, cytarabine.” NCT04501614 ↗ “MVAC regimen: Methotrexate (30 mg/m2 IV bolus, D1, 15, 22), Vinblastine (3 mg/m2 IV bolus, D2, 15, 22), Doxorubicin (30 mg/m2 IV bolus D2), Cisplatin (70 mg/m2 D2), every 4 weeks” NCT03296306 ↗ “Immunosuppressive/immunomodulatory agents including but not limited to antimalarials (i.e. hydroxychloroquine), methotrexate, azathioprine and corticosteroids (i.e. prednisone)” NCT04809623 ↗ “The Sponsor is developing folate-based liposomes encapsulating methotrexate (FBL-MTX) as a putative therapy for RA, by intravenous (IV) or subcutaneous (SC) administration.” NCT06565273 ↗ “hydroxychloroquine 200 mg TID PO+ methotrexate 2.5 mg BID twice a week PO+ capecitabine 1000 mg/m2 PO BID for 14 days+ bevacizumab 7.5 mg/m2 IV on day 1, every 3 weeks.” NCT06949982 ↗ “The following DMARDs were permitted in this study: methotrexate (MTX), chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide.” NCT00531817 ↗ “In case of previous adverse event leading to thiopurine discontinuation methotrexate 15 mg/week sc. in combination with oral folic acid 5mg/week will be prescribed.” NCT06059989 ↗ “Effect of One-week Discontinuation of Methotrexate on Immunogenicity of COVID-19 Booster Vaccination in Patients With Rheumatoid Arthritis: A Randomized Pilot Study” NCT05313061 ↗ “A Study to Investigate the Effect of Multiple Doses of JNJ 39758979 on Methotrexate Pharmacokinetics in Rheumatoid Arthritis Patients on a Stable Methotrexate Dose” NCT01442545 ↗ “administer methotrexate (MTX) or thiotepa (for patients intolerant to MTX) combined with R-CHOP and orelabrutinib for six cycles, with each cycle lasting 21 days.” NCT06901999 ↗ “Cyclosporine A (CsA) + Mycophenolate mofetil dispersible tablets (MMF) + short-term low-dose methotrexate (MTX) + rabbit anti-human antithymocyte globulin (ATG)” NCT06816134 ↗ “Lumbar puncture: cytarabine 50mg+dexamethasone 5mg+methotrexate 10mg, intrathecal injection, once a month after remission, a total of 4-6 courses of treatment.” NCT06861348 ↗ “Disease-modifying anti-rheumatic drugs included methotrexate, chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide.” NCT00720798 ↗ “Methotrexate (MTX) is one of the critical components for treating all forms of acute lymphoblastic leukemia (ALL), which is the most common pediatric cancer.” NCT02011022 ↗ “durvalumab 20 mg/kg q4w plus tremelimumab 1 mg/kg q4w × 4, then durvalumab 10 mg/kg q2w), or SoC (cetuximab, a taxane, methotrexate, or a fluoropyrimidine).” PMID 32294530 ↗ Apr 2020 “methotrexate 10-25 mg/week, sulfasalazine 1-2 g/day, hydroxychloroquine 35 mg/kg/week, prednisolone 7.5 mg/day, and infliximab 3 mg/kg during first 6 months” NCT00908089 ↗ “Patients allocated to receive conventional chemotherapy will be treated with methotrexate (1 mg/kg intramuscular) with rescue of folinic acid (15mg orally).” NCT04756713 ↗ “Standard Chemotherapy (which includes cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, 6-mercaptopurine, etoposide, and cytarabine” NCT03319901 ↗ “Includes vincristine, daunorubicin, cyclophosphamide, pegaspargase, prednisone, dexamethasone, cytarabine, 6-mercaptopurine, and high-dose methotrexate.” NCT07495631 ↗ “Patients will receive methotrexate or remain on pre-existing conventional synthetic disease-modifying anti-rheumatic drug (DMARD) if already prescribed.” NCT03652961 ↗ “Methotrexate, hydrocortisone and cytarabine are combined into one preparation for intrathecal administration at multiple time points during treatment.” NCT07059975 ↗ “Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;” NCT04881838 ↗ “The 5 chemotherapy drugs used in the Induction part of treatment are vincristine, cisplatin, cyclophosphamide, etoposide and high-dose methotrexate.” NCT02875314 ↗ “compare the efficacy and safety of camrelizumab in combination with adriamycin, cisplatin, ifosfamide and methotrexate in study population in China” NCT04294511 ↗ “RCOG guidelines (No. 38February 2010 ) recommends the use of rescue regimen of alternating methotrexate( MTX) and leucoverin for 8 days (class D).” NCT03280979 ↗ “CMF: Cyclophosphamide (600 mg/m2 IV bolus), methotrexate (40 mg/m2 IV bolus), 5-fluorouracil (600 mg/m2 IV bolus) on Day 1 of Cycles 8 through 10” NCT01998906 ↗ “R-HDS : Rituximab supplemented high-dose (Cyclophosphamide,Ara-C, Methotrexate, Etoposide, Cis-Platin) sequential chemotherapy with autografting.” NCT00355199 ↗ “DD-MVAC consists of Methotrexate 30 mg/m2 iv day 1, Vinblastine 3 mg/m2 iv day 2, Cisplatin 70 mg/m2 iv day 2 and Doxorubicin 30 mg/m2 iv day 2.” NCT03674424 ↗ “concomitantly leflunomide (no loading dose, 10 mg/day) and methotrexate (starting at 7.5 mg/week and titrating up to 15 mg/week) for 20 weeks.” NCT00563849 ↗ “The CNS relapse rate of the R-CHOP regimen combined with MTX (methotrexate) intrathecal in high CNS-IPI DLBCL patients is approximately 12%.” NCT05257018 ↗ “methotrexate 7.5-15 mg once weekly hydroxychloroquine 200 mg twice daily sulfasalazine 500 mg to 3 g once daily leflunomide 20 mg once daily” NCT05671497 ↗ “Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, IT medications, G-CSF, Rituximab” NCT01046825 ↗ “The longest treatment phase in both protocols is maintenance therapy, which is composed of 6-Mercaptopurine (6MP) and Methotrexate (MTX).” NCT02912676 ↗ “methotrexate orally weekly at initial dose of 10 mg rising to 20 mg weekly over 4 weeks in 2.5 mg increments, continued up to month 24” NCT00480272 ↗ “polatuzumab vedotin x1; dexamethasone x 5; vincristine x1, cyclophosphamide x 3; doxorubicin x1; methotrexate x; rituximab 2x; ITT x1” NCT05253495 ↗ “Although methotrexate (MTX) is the consensual first-line disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis (RA)” PMID 28866645 ↗ Sep 2017 “Complete cessation of non-biologic DMARD therapy (single or combination of methotrexate, sulphasalazine and/or hydroxychloroquine)” NCT02219347 ↗ “Methotrexate(MTX) and/or 1 DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)” NCT01211834 ↗ “Cyclosporine or tacrolimus(CNI)+Mycophenolate mofetil(MMF)± Short Course Methotrexate(MTX)+Anti-human T-lymphocyte Globulin（ATG）” NCT06949267 ↗ “Methotrexate 12,5 mg + Cytarabine 50 mg + Prednisolone 40 mg. injected intrathecally x12 during induction/consolidation therapy” NCT00795756 ↗ “Tacrolimus- 0.03mg/kg/24h IV beginning day-3 Methotrexate- 15mg/m2 IV day +1 then 10mg/m2 IV on days 3, 6, 11 post transplant.” NCT00360685 ↗ “Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care” NCT03088059 ↗ “All patients will continue to receive the same does of methotrexate (MTX) during the study as received prior to the study.” NCT00202852 ↗ “Standard-of-care DMARD therapy, including methotrexate, sulfasalazine, leflunomide, minocycline, and/or hydroxychloroquine” NCT01313208 ↗ “methotrexate 30mg/m² + vinblastine 6mg/m² (IV infusion) once/week for 6 months, then every other week from months 7 to 12” NCT06081400 ↗ “Patients receive methotrexate subcutaneously once weekly in the absence of disease progression or unacceptable toxicity.” NCT00278265 ↗ “Standard AMVAC dose is as follows: methotrexate 30mg/m2, vinblastine 3mg/m2, doxorubicin 30mg/m2, and cisplatin 70mg/m2.” NCT04506554 ↗ “Active Comparator: one of 3 pre-determined choices of therapies: capecitabine or eribulin or high-dose IV methotrexate.” NCT03613181 ↗ “diclofenac 50 mg twice a day, prednisone 5mg once daily, methotrexate 10mg once weekly or sulfasalazine 500 twice daily” NCT06594822 ↗ “Mix: Methotrexate 8-12 milligrams, Hydrocortisone 16-24 milligrams and Cytarabine 24-36 milligrams, intrathecal, day 19” NCT02451774 ↗ “The intervention group will receive baricitinib in combination with methotrexate after failure of conventional therapy” NCT07357649 ↗ “Hyper-CVAD-A: Cyclophosphamide ,Vincristine , Doxorubicin , Dexamethasone ; Hyper-CVAD-B: Methotrexate , Cytarabine .” NCT07564453 ↗ “including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine.” NCT05247203 ↗ “Subjects will be on a stable dose of methotrexate 12.5 to 20 mg per week and will be started on infliximab 5 mg/kg.” NCT00462072 ↗ “week 0 and 8, doxorubicin; week 2 and 10, ifosfamide; week 4, 5, 12 and 13, methotrexate; week 6 and 14, cisplatin” NCT03390946 ↗ “* Methotrexate 5 mg/m\^2 (Days +1, +3, and +6). Unrelated donor recipients will receive a fourth dose on Day +11.” NCT00912223 ↗ “Can be FK506 (Tacrolimus/Prograf®), mycophenolate mofetil ((MMF)/Cellcept®), or methotrexate (MTX, amethopterin)” NCT01020539 ↗ “IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement” NCT05658640 ↗ “IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement” NCT07175415 ↗ “IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement” NCT05740449 ↗ “IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement” NCT05745714 ↗ “IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement” NCT05751044 ↗ “Methotrexate (30 mg /m²) and Vinblastine 3 (mg /m²) day 1; Adriamycin 30 mg /m² and Cisplatin 70 mg /m² in day2” NCT02969083 ↗ “First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen)” NCT06454266 ↗ “Methotrexate, an antimetabolite, may be given when necessary to get chemotherapy past the blood brain barrier.” NCT05581030 ↗ “Methotrexate (MTX): 1 g/m² IV over 24h (Day 1) with urine alkalinization (pH \>7.0) and leucovorin rescue.” NCT07059156 ↗ “Day 1 Actinomycin D 1mg/m2, Paclitaxel 80mg/m2, Methotrexate Day 4 Oxaliplatin 100mg/m2 Pegfilgrastim 6mg” NCT01782339 ↗ “oral bcl-2 inhibitor plus IM2(Ifosfamide plus Mitoxantrone or Idarubicin plus methotrexate) chemotherapy” NCT05576532 ↗ “* Methotrexate - Initial: 10 to 15 mg/m2 once weekly; adjust gradually up to 20 to 30 mg/m2 once weekly” NCT05871086 ↗ “Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis” NCT06048224 ↗ “Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC)” NCT01716039 ↗ “Standard of care treatment for RA, such as Methotrexate or other disease-modifying antirheumatic drugs.” NCT01548768 ↗ “Methotrexate 5 mg/m2 Intravenous Pyelogram (IVP) will be administered on Days +1, +3 and +6 post-HSCT.” NCT00096460 ↗ “methotrexate, basiliximab, daclizumab, inolimomab, denileukin diftitox, alemtuzumab, ATG+ etanercept” NCT02694770 ↗ “Methotrexate 15 to 25 mg/week (or ≥10 mg/week if there was documented intolerance to higher doses).” NCT03120949 ↗ “Methotrexate (MTX) is a medication used to treat inflammation in people with rheumatoid arthritis.” NCT01949116 ↗ “High-dose methotrexate : 8-12 g/m2 (MTX chemotherapy requires blood drug concentration monitoring)” NCT05926492 ↗ “IT methotrexate given Intrathecally to all patients who are CNS negative at study entry on day 16” NCT01324180 ↗ “low-dose methotrexate (MTX), mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib.” NCT05132166 ↗ “Patients then receive cyclophosphamide IV, methotrexate IV, and fluorouracil IV on days 1 and 8.” NCT00433589 ↗ “or methotrexate 10-25 mg/week orally or subcutaneously as above, regardless of the preparation” NCT06297096 ↗ “include Cyclosporine (CsA),Methotrexate (MTX), Mycopherol ester (MMF) and Antithymic Globulin” NCT05149365 ↗ “the immunomodulatory agent was azathioprine 1-2mg/kg per day or methotrexate 10-25 mg/m2 week” NCT05043870 ↗ “Patients were treated with Methotrexate (MTX)and Tripterygium wilfordii Hook F（TwHF）placebo.” NCT03337815 ↗ “One course of high-dose Methotrexate (optional) followed by 5 courses of API, every 21 days” NCT03643133 ↗ “SMILE (dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide) chemotherapy” PMID 35708709 ↗ Jul 2022 “Methotrexate (MTX) is a folic acid antagonist-an antiproliferative drug, as it is known.” NCT06641128 ↗ “High-dose methotrexate-based regimen (HDMTX; 500 mg/m² to 3 g/m² infused up to 24 hours)” NCT02013167 ↗ “short-term low-dose methotrexate (MTX) + rabbit anti-human antithymocyte globulin (ATG)” NCT07562568 ↗ “Early and delayed consolidation (high-dose Methotrexate, high-dose Cytarabine, PegASP).” NCT04179929 ↗ “Early and delayed consolidation (high-dose Methotrexate, high-dose Cytarabine, PegASP).” NCT07443592 ↗ “etoposide, methotrexate, actinomycin D/cyclophosphamide, vincristine, alternate weekly” NCT05139095 ↗ “DMARDs (methotrexate: MTX, leflunomide: LEF) were taken orally for at least 12 months.” NCT01600521 ↗ “1. Sulphasalazine + Hydroxychloroquine OR Prednisolone plus Methotrexate and steroids” NCT02466581 ↗ “carboplatin, paclitaxel, docetaxel, 5-Fu, methotrexate, gemcitabine and capecitabine” NCT03529279 ↗ “methotrexate (M, 3.5 g/m²) is administered as a 3-hour intravenous infusion on day 1” NCT07604987 ↗ “Patients receive also Methotrexate (15 mg weekly) and Prednisolone (0.5 mg/daily).” NCT00664599 ↗ “Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.” NCT02551575 ↗ “azathioprine, methotrexate, mycophenolate mofetil, corticosteroids, antimalarials” NCT04726553 ↗ “Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.” NCT03324412 ↗ “Cycle 2: VP + HD-MTX regimen (Vincristine, Prednisone + High-Dose Methotrexate).” NCT06930105 ↗ “vincristine, cyclophosphamide, cisplatin, etoposide with or without methotrexate” NCT06193759 ↗ “Administer methotrexate at 8000 mg/m² as a 24 hour IV infusion on days 15-36-57.” NCT02265770 ↗ “By administering a single intramuscular dose of 50mg / m2 / Sc of Methotrexate.” NCT05136274 ↗ “Non-biologic DMARDs (including methotrexate) according to current best practice” NCT01251120 ↗ “Tacrolimus and low-doses of methotrexate will be used for prophylaxis of GVHD.” NCT01208896 ↗ “including cyclophosphamide(CYC), methotrexate(MTX) and azathioprine(AZA) etc.” NCT03096275 ↗ “1000 mg of Metformin table taken orally daily plus Methotrexate 7.5 mg weekly” NCT04068246 ↗ “IM or S.C Methotrexate plus Silymarin tablets 140 mg once daily for 3 months.” NCT06724952 ↗ “fixed-dose MAD (Methotrexate, L-asparaginase and Dexamethasone) chemotherapy” NCT03246750 ↗ “receive cyclophosphamide, methotrexate, and fluorouracil (CMF) for 4 courses” NCT00003953 ↗ “Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in” PMID 20574649 ↗ Jun 2010 “Cyclophosphamide, Methotrexate and Sirolimus will be administrated orally.” NCT02517918 ↗ “Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hours (d1-2, 15-16)” NCT00844298 ↗ “Cisplatin, vincristin, etoposide, cyclophosphamide, high-dose methotrexate” NCT07291102 ↗ “Intraventricular rituximab plus methotrexate (MTX) on day 4 of each week.” NCT00221325 ↗ “Methotrexate at D1 (24H infusion, alkaline hydration, leucovorin rescue):” NCT03599960 ↗ “treated with high-doses of methotrexate and cytarabine, followed by R-HDS” PMID 26282634 ↗ Aug 2015 “Regimen A:CODOX-M:cyclophosphamide,epirubicin,vincristine,methotrexate.” NCT03558412 ↗ “Cytoxan,Mesna,Adriamycin,Vincristine,Methotrexate,Leucovorin,Cytarabine” NCT00774332 ↗ “* Dose Dense Methotrexate - Vinblastine - Adriamycin - Cisplatin (MVAC)” NCT06290687 ↗ “Allopurinol is added to standard oral 6-mercaptopurine and methotrexate” NCT03022747 ↗ “Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hr (d1-2, 15-16)” NCT01429610 ↗ “For subjects who are inadequate responders to methotrexate (MTX): MTX.” NCT03660059 ↗ “IT cytarabine, methotrexate, and either prednisolone or hydrocortisone” NCT03793478 ↗ “HD-MTX: High-dose methotrexate with leucovorin rescue in cycle 4,6,8.” NCT07493161 ↗ “First line treatments：low risk：Methotrexate or ACTD; high risk：EMA-CO” NCT03785574 ↗ “L-VAMP (leucovorin, vincristine, aracytin, methotrexate, prednisone)” NCT04475731 ↗ “Methotrexate 5 mg/m2 IV on days +1, +3, +6, and +11 post-transplant.” NCT00520130 ↗ “Methotrexate: 5 mg/m\^2 IV over 15 minutes on days 1, 3, 6, and 11.” NCT02356159 ↗ “Drug:Methotrexate 1g/m2 d1,IV (in the vein) , used in cycle 1,3,5” NCT02042690 ↗ “Intrathecal chemotherapy: methotrexate 12 mg + dexamethasone 2 mg” NCT06034561 ↗ “Methotrexate 30 mg/m2 IV push or infusion over 2-3 minutes. Day 1” NCT01031420 ↗ “PREDNISOLONE 10mg orally ONCE DAILY and Methotrexate 25 mg / day” NCT01724268 ↗ “adverse effects of methotrexate (MTX) in women refusing surgery” NCT05839561 ↗ “200 mg SC Day 1, Placebo Day 15, Placebo Day 84 + Methotrexate” NCT01008852 ↗ “methotrexate, leflunomide, hydroxychloroquine or sulfasalazine” NCT03863405 ↗ “methotrexate (12 mg) cytarabine (30 mg) hydrocortisone (20 mg)” NCT00466258 ↗ “methotrexate, leflunomide, hydroxychloroquine or sulfasalazine” NCT05447520 ↗ “DMARD therapy can include methotrexate or other DMARD therapy” NCT00747214 ↗ “methotrexate- leflunomide- sulfasalazine- hydroxychloroquine” NCT06640309 ↗ “GVHD prophylaxis consisted of cyclosporine and Methotrexate.” NCT00152139 ↗ “Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT” NCT01679860 ↗ “oral methotrexate (10-25 mg) was administered once weekly.” PMID 40388166 ↗ May 2025 “inadequate response to previous methotrexate (MTX) therapy” NCT02833350 ↗ “Temporary discontinuation of methotrexate for 1 or 2 weeks” NCT05069714 ↗ “a continuous regimen of methotrexate and 6-mercaptopurine.” NCT00700544 ↗ “cyclophosphamide-methotrexate-5-fluorouracil (CMF) therapy” PMID 23490655 ↗ Mar 2013 “Methotrexate; 5 mg/m\^2/day, IV push, days +1, +3, +6, +11” NCT01751997 ↗ “Capizzi maintenance: iv methotrexate and peg-asparaginase” NCT00222612 ↗ “R-HD MTX: Rituximab 375mg/m2 d0, Methotrexate 3.5g/m2 d1” NCT05164770 ↗ “Methotrexate IV (3g/m² during 30 minutes) day1 and day15” NCT00863460 ↗ “both azathioprine (AZA) and methotrexate (MTX) are used.” NCT05040464 ↗ “50 mg/m2 intramuscular methotrexate was given on day one” NCT01662167 ↗ “Conventional DMARDs include methotrexate (Imutrexate®)” NCT06753565 ↗ “High-Dose Methotrexate (MTX) + Cytarabine] ± Rituximab” NCT06520163 ↗ “Intrathecal methotrexate, cytarabine and prednisolone” NCT00991744 ↗ “Natrunix Versus Methotrexate in Rheumatoid Arthritis” NCT05363917 ↗ “methotrexate IV and fluorouracil IV on days 1 and 8” NCT00024102 ↗ “including ruxolitinib, basiliximab, or methotrexate” NCT07572669 ↗ “Asciminib, Dasatinib, Prednisone, and Methotrexate” NCT06773936 ↗ “abatacept plus methotrexate (MTX)-treated patients” PMID 26063454 ↗ Jun 2015 “Methotrexate initially 15mg/wk; max dose 25 mg/wk.” NCT03828019 ↗ “Methotrexate: 25 mg/m2 on day 1, 8, TIT on day 1” NCT05827549 ↗ “methotrexate 4 g/m(2) intravenously (i.v.) Day 1” PMID 23242601 ↗ Dec 2012 “methotrexate: 3-3.5 g/m2 intravenously on day 1” NCT06445257 ↗ “or plus mycophenolate mofetil, or methotrexate.” NCT00972660 ↗ “docetaxel, cetuximab, methotrexate, paclitaxel” NCT03769506 ↗ “Part B: high dose methotrexate and cytarabine.” NCT07294677 ↗ “Golimumab (CNTO 148) with Methotrexate (MTX)” NCT00207714 ↗ “M: methotrexate: 40 mg/m² i.v. days 1 and 8” NCT00174655 ↗ “methotrexate (7.5 mg/m2/day) Day 1, 3 and 6” NCT00745420 ↗ “Methotrexate 30mg/m2 intravenously on day 1” NCT03472274 ↗ “ATRA, ATO and methotrexate (MTX) treatment.” NCT01987297 ↗ “50 mg etanercept once weekly + methotrexate” NCT00858780 ↗ “ADX-2191 (intravitreal methotrexate 0.8%)” NCT04136366 ↗ “Mercaptopurine Methotrexate Mitoxantrone” NCT02551718 ↗ “Combination Methotrexate and Infliximab” NCT00432432 ↗ “Methotrexate/hydrocortisone/cytarabine” NCT02553460 ↗ “a high-dose methotrexate-based regimen” NCT05578378 ↗ “methotrexate/hydrocortisone/cytarabine” NCT03194932 ↗ “Methotrexate/hydrocortisone/cytarabine” NCT02433483 ↗ “methotrexate/hydrocortisone/cytarabine” NCT05656248 ↗ “Methotrexate/Hydrocortisone/Cytarabine” NCT03164057 ↗ “* Methotrexate * Doxorubicin liposomal” NCT00801580 ↗ “methotrexate/hydrocortisone/cytarabine” NCT02676323 ↗ “Methotrexate 15-20 mg/m2 once per week” NCT00323960 ↗ “Methotrexate, 30 mg/m2 IV bolus, Day 1” NCT04047693 ↗ “methotrexate/hydrocortisone/cytarabine” NCT03515200 ↗ “Methotrexate 1500 mg/m2 12 h IV 1 day” NCT03479918 ↗ “methotrexate (30 мг/м2, i.m., weekly)” NCT03390387 ↗ “Methotrexate 1000 mg/m2 12 h IV 1 day” NCT02842931 ↗ “Methotrexate (e.g. Lantarel®, Metex®)” NCT02779114 ↗ “Once a week Methotrexate 15 to 25 mg” NCT03403140 ↗ “Methotrexate: 5 g/m2 d 8, 22, 36, 50” NCT02396043 ↗ “Methotrexate 8-12 g/m² intravenously” NCT07142863 ↗ “methotrexate (Rheumatrex and others)” NCT00132691 ↗ “Methotrexate (oral administration)” NCT02467504 ↗ “Methotrexate (MTX) 3.5g/m2 drip D1” NCT05347641 ↗ “stable dose of methotrexate (MTX)” NCT02889796 ↗ “Methotrexate, 3.0g/m2/d iv, day 1” NCT02764281 ↗ “Mercapto, Methotrexate, Mitomycin” NCT02788201 ↗ “Rituximab-Methotrexate-Cytarabin” NCT06830421 ↗ “Methotrexate 40 mg/m2 weekly X 5” NCT01667289 ↗ “methotrexate 800 mg/m2 i.v. d 22” NCT00517894 ↗ “Day +1: Methotrexate 7.5mg/m2 IV” NCT00920972 ↗ “Methotrexate 3.5 g/m² i.v. (d1)” NCT02531841 ↗ “Methotrexate: 12g/m2 (3 cycles)” NCT01459484 ↗ “METHOTREXATE: 30 mg/m² on day 1” NCT02818725 ↗ “1. Methotrexate 30 mg/m2 IV D1” NCT03549715 ↗ “Methotrexate: 3.5 g/m², Day 2” NCT07677813 ↗ “Methotrexate 12mg IT on day 4” NCT01184885 ↗ “MTX: Methotrexate,Leucovorin” NCT01083342 ↗ “M = Methotrexate 12000 mg/m2” NCT04351308 ↗ “or Methotrexate (\<=15mg/w)” NCT04124861 ↗ “Methotrexate 7.5 mg/m2 IV” NCT01565616 ↗ “Methotrexate 2g/ m2，IV d1” NCT01933282 ↗ “methotrexate (MTX)-naive” NCT00048542 ↗ “Methotrexate: 25mg/week.” NCT01491815 ↗ “Methotrexate 3.5g/ｍ2 d1” NCT05097443 ↗ “methotrexate (MTX)” NCT02504671 ↗ “methotrexate (MTX)” NCT04203108 ↗ “methotrexate (MTX)” NCT00144521 ↗ “methotrexate (MTX)” NCT07185373 ↗ “dd 7, Methotrexate” NCT01516593 ↗ “MTX (methotrexate)” NCT00602667 ↗ “Drug: Methotrexate” NCT03206671 ↗ “• Methotrexate” NCT07124078 ↗ “methotrexate” NCT06297096 ↗ “Methotrexate” NCT03965728 ↗ “Methotrexate” NCT06496178 ↗ “methotrexate” NCT05000216 ↗ “Methotrexate” NCT02643823 ↗ |
| Known as | Abitrexate | “Abitrexate” NCT01168219 ↗ |
| Known as | ADX-2191 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04136366 ↗ |
| Known as | Amethopterin | “Can be FK506 (Tacrolimus/Prograf®), mycophenolate mofetil ((MMF)/Cellcept®), or methotrexate (MTX, amethopterin)” NCT01020539 ↗1“Amethopterin” NCT02220985 ↗ |
| Known as | amethopterin (previous name for MTX) | “amethopterin (previous name for MTX)” NCT00658047 ↗ |
| Known as | Biodim | “Methotrexate Biodim®” NCT03103334 ↗ |
| Known as | ddMTX-LDE | “Methotrexate carried by a lipid nanoemulsion (ddMTX-LDE)” NCT03516903 ↗ |
| Known as | Emthexate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04532736 ↗ |
| Known as | FBL-MTX | “The Sponsor is developing folate-based liposomes encapsulating methotrexate (FBL-MTX) as a putative therapy for RA, by intravenous (IV) or subcutaneous (SC) administration.” NCT06565273 ↗ |
| Known as | HD-MTX | “This Phase II, multi-institutional study evaluates the safety of hospital discharge at higher serum methotrexate (MTX) levels in children, adolescents, and young adults with...” NCT07560826 ↗9“Those patients will be randomised to two different treatment schedules of chemotherapy either with VEC or VEC+ high dose methotrexate (VEC +HD-MTX).” NCT02265770 ↗ “HD-MTX IV 5,000 mg/m2 I.V. over 4hr on day 0, 14, 28, 42 of SER interim maintenance schedule” NCT02339350 ↗ “High-dose Methotrexate (HD-MTX) 3.5 g/m² intravenously over 4 hours on Day 1 of each cycle” NCT07002099 ↗ “Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma” NCT01176981 ↗ “High dose methotrexate (HD MTX) 5 gm/m2 IV over 4 hours on Day 1 with leucovorin rescue” NCT00187070 ↗ “high-dose methotrexate (HD-MTX)-based first-line regimens” NCT07350850 ↗ “HDMTX 2 g/m2 IV over 2 hours, every 8 weeks” NCT00187057 ↗ “High-dose Methotrexate (8 gm/m2; HD-MTX)” NCT02422641 ↗ “high-dose methotrexate (HD-MTX)” NCT05398224 ↗ |
| Known as | Imutrexate | “Conventional DMARDs include methotrexate (Imutrexate®)” NCT06753565 ↗ |
| Known as | Intrathecal Methotrexate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02660762 ↗ |
| Known as | IT MTX | “Iodine-131-labeled Monoclonal Antibody BC8 (anti-CD45), 131I-BC8; plus Busulfan, BU, NSC-750; Cyclophosphamide, CTX, NSC-26271; followed by Allogeneic Bone Marrow, ABM; with,...” NCT00002554 ↗ |
| Known as | Lantarel | “Methotrexate (e.g. Lantarel®, Metex®)” NCT02779114 ↗ |
| Known as | LDM | “A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery...” NCT01594333 ↗1“anti-inflammatory agent commonly used in rheumatoid arthritis (low dose methotrexate (LDM))” NCT02576067 ↗ |
| Known as | LDMTX | “The AIDS Clinical Trials Group Study A5314 sought to lower inflammation with low-dose methotrexate (LDMTX).” PMID 39287554 ↗ Aug 2024 |
| Known as | Metex | “Patients were randomized to receive the test drug, a prefilled pen (Metex(®) PEN/Metoject(®) PEN), or the reference drug, a prefilled syringe (Metex(®)/Metoject(®)), at doses...” PMID 25125973 ↗ Aug 20141“Methotrexate (e.g. Lantarel®, Metex®)” NCT02779114 ↗ |
| Known as | Metex() PEN | “Patients were randomized to receive the test drug, a prefilled pen (Metex(®) PEN/Metoject(®) PEN), or the reference drug, a prefilled syringe (Metex(®)/Metoject(®)), at doses...” PMID 25125973 ↗ Aug 2014 |
| Known as | Methotrexate (MTX) | “Methotrexate (MTX)” NCT03414502 ↗ |
| Known as | methotrexate (Rheumatrex and others) | “methotrexate (Rheumatrex and others)” NCT00132691 ↗ |
| Known as | Methotrexate Injection USP | “A Prospective, Randomized, Double-masked, Dosing-frequency-controlled, Multicenter Clinical Trial Evaluating the Safety and Activity of Intravitreally Injected ADX-2191...” NCT07402876 ↗ |
| Known as | Methotrexate tablets | “Methotrexate tablets is a folic acid antagonist, which belongs to an anti-rheumatic drug to improve the condition” NCT05380934 ↗ |
| Known as | Methotrexatum dinatricum | “Tested investigational medicinal product: Methotrexate (Methotrexatum dinatricum 2,5 mg tbl.).” NCT00651040 ↗ |
| Known as | Metoject | “Patients were randomized to receive the test drug, a prefilled pen (Metex(®) PEN/Metoject(®) PEN), or the reference drug, a prefilled syringe (Metex(®)/Metoject(®)), at doses...” PMID 25125973 ↗ Aug 20141“Methotrexate (Metoject® prefilled pen)” NCT07486843 ↗ |
| Known as | Metoject() PEN | “Patients were randomized to receive the test drug, a prefilled pen (Metex(®) PEN/Metoject(®) PEN), or the reference drug, a prefilled syringe (Metex(®)/Metoject(®)), at doses...” PMID 25125973 ↗ Aug 2014 |
| Known as | MTX | “Participants must have been treated with and tolerated Methotrexate (MTX) treatment at dosages from 10 to 25 milligram per week (mg/week) inclusive, for a minimum of 6 months...” NCT01679951 ↗252“Cycle 5 - 10 Drug: Methotrexate * Intravenous methotrexate at 3.5g/m2 for 6 hours will be given on day 1 each 21-day cycle 【Leucovorin Calcium (CF): 15mg/m², rescue begins 12...” NCT06646211 ↗ “The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG),...” NCT04118556 ↗ “We will recruit hemodynamically stable women with a confirmed PPUL to be randomized to one of three strategies: 1) Uterine evacuation followed by methotrexate (MTX) for some...” NCT02152696 ↗ “This Phase II, multi-institutional study evaluates the safety of hospital discharge at higher serum methotrexate (MTX) levels in children, adolescents, and young adults with...” NCT07560826 ↗ “Methotrexate (MTX) is an antimetabolite drug showing a competitive reversible binding concerning natural dihydrofolates and acting as an inhibitor of the...” NCT06554470 ↗ “In another study (Protocol #89-I-18), we evaluated treatment with GC and weekly oral doses of methotrexate (MTX) in 15 patients with Takayasu's arteritis, in whom disease...” NCT00001256 ↗ “This multicenter, randomized, crossover study compared preference, ease of use, acceptability, satisfaction, and safety of repeated subcutaneous (SC) self-administrations with...” PMID 25125973 ↗ Aug 2014 “Seventy-five children with definite JDMS will be enrolled in a 24-month prospective, randomized, multicentered trial comparing 3 treatments: oral prednisone (P), combination of...” NCT00035958 ↗ “OBJECTIVE: Two randomised controlled trials, AMBITION (NCT00109408) and ADACTA (NCT01119859), showed tocilizumab (TCZ) monotherapy superior to methotrexate (MTX) and adalimumab...” PMID 28955499 ↗ Sep 2017 “The purpose of the study is to compare the effects of methotrexate (MTX) alone or in combination with intravenous (IV) methylprednisolone (MP) or infliximab (IFX) on...” NCT00396747 ↗ “The aim of this trial was to assess the possibility of discontinuing treatment with adalimumab (ADA) while maintaining remission in patients with RA with established disease in...” PMID 26819752 ↗ Jan 2016 “The aim of the study is to identify the efficacy and safety of methotrexate (MTX) combined corticosteroid treatment for grade III-IV acute graft-versus-host disease (aGVHD)...” NCT04958538 ↗ “Patients received local and systemic therapies: intravitreal methotrexate (MTX, 400 μg, 0.1 mL) injections for 1 year (total 16 injections) and six cycles of the rituximab (375...” PMID 34249763 ↗ Jun 2021 “Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow...” NCT01188798 ↗ “Methotrexate (MTX) co-medication can improve the therapeutic effect of biological therapies (e.g. Tumor necrosis factor (TNF) -inhibitors) in rheumatoid arthritis (RA), but its...” NCT03148860 ↗ “Yisaipu® was introduced only during the active state and was switched to DMARDs, methotrexate(MTX), sulfasalazine(SSZ) and hydroxychloroquine(HCQ), after disease remission (ESR...” NCT03411798 ↗ “Patients receive methotrexate (MTX) intra-arterially over 10 minutes, cyclophosphamide IV over 10 minutes, and etoposide phosphate IV over 10 minutes on days 1 and 2 in...” NCT00074178 ↗ “In this randomized controlled trial, we assessed the effects of three consecutive intra-silicone oil (SO) injections of methotrexate (MTX) on the outcomes of surgery for...” PMID 39572739 ↗ Nov 2024 “Methotrexate (MTX)-naive patients with early progressive RA were randomly assigned (1:1:1:1) to one of four treatment groups: 4 mg/kg TCZ+MTX, 8 mg/kg TCZ+MTX, 8 mg/kg...” PMID 26511996 ↗ Oct 2015 “OBJECTIVE: To compare the relative bioavailability, safety and tolerability of oral methotrexate (MTX) and subcutaneous (SC) MTX administered via an auto-injector (MTXAI) in...” PMID 24728329 ↗ Apr 2014 “To assess the maximum tolerated dose (MTD) of temozolomide (TMZ) in combination with methotrexate (MTX) and rituximab (RTX) when administered prior to twice daily fractionated...” NCT00068250 ↗ “The purpose of this study is to determine the safety and efficacy of the use of the combination therapy adalimumab (ADA) every other week (EOW) with methotrexate (MTX) in...” NCT02196701 ↗ “This study is intended to evaluate the efficacy and safety of Iguratimod alone or Iguratimod in combination with Methotrexate (MTX) versus Methotrexate alone in patients with...” NCT01548001 ↗ “treatment with tofacitinib monotherapy versus tofacitinib or adalimumab (ADA) in combination with methotrexate (MTX) in patients with rheumatoid arthritis (RA) with inadequate...” PMID 31673419 ↗ Oct 2019 “Triple therapy was administered with methotrexate (MTX), cytosine arabinoside (ARA-C) and hydrocortisone, days 1, 8, 15 and 22 (five doses total prophylactic between prephase...” NCT01358201 ↗ “Triple therapy was administered with methotrexate (MTX), cytosine arabinoside (ARA-C) and hydrocortisone, days 1, 8, 15 and 22 (five doses total prophylactic between prophase...” NCT01376427 ↗ “csDMARDs may include one or two of the following: methotrexate (MTX), hydroxychloroquine or chloroquine, sulfasalazine, and/or leflunomide (combination of leflunomide and MTX...” NCT02873936 ↗ “In patients with early RA (the ASPIRE trial), ACR/EULAR Boolean, CDAI, and SDAI remission rates at 6-7 months were 4-6% for methotrexate (MTX) alone versus 11-14% for...” PMID 27696724 ↗ Mar 2017 “The product FBL-MTX consists of Methotrexate (MTX) encapsulating liposomes functionalized with a folate peptide (SP-DS3), which targets activated macrophages of rheumatoid...” NCT05117593 ↗ “This study is conducted to assess the relative bioavailability of MTX administered subcutaneously via a prefilled pen (50mg/mL) compared with MTX administered via IM injection...” NCT02097173 ↗ “Primary endpoint was the proportion of patients achieved a 50% improvement of American College of Rheumatology criteria (ACR50) in TwHF+rhTNFR-Fc vs. methotrexate (MTX) group...” PMID 37657525 ↗ Aug 2023 “The objective of this study is to assess the efficacy of certolizumab pegol (CZP) with methotrexate (MTX) compared with MTX-alone in patients with early-stage rheumatoid arthritis (RA)” NCT01451203 ↗ “Methotrexate (MTX) 25 mg once weekly administered subcutaneously (sq) or intramuscularly (im) is an efficient therapy to induce and maintain steroid free remission in patients with CD.” NCT01393405 ↗ “Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX” NCT01039688 ↗ “At week 50, 6 out of 8 (75%) patients from the original MTX (methotrexate) group versus 10 out of 18 (56%) patients from the original MTX+TNFi group were in DAS-CRP remission” PMID 31521192 ↗ Sep 2019 “Both treatment regimens use high-dose i.v. MTX, but only the HIT-SKK regimen also uses intraventricular administration of MTX directly into the CSF in addition to i.v. MTX” NCT07291102 ↗ “To investigate the effects of short-term discontinuation of methotrexate (MTX) on disease activity in patients with rheumatoid arthritis (RA) taking a stable dose of MTX.” PMID 31823141 ↗ Dec 2019 “Methotrexate (MTX) and adalimumab are well-recognized treatments of rheumatoid arthritis (RA), the efficacy of which may be driven by intracellular polyglutamates (PGs).” PMID 29402521 ↗ Feb 2018 “Patients were randomly assigned (1:1) to receive low-dose prednisone plus methotrexate (MTX + LowPred) or standard-dose prednisone alone (standPred) for nine months.” PMID 40974866 ↗ Sep 2025 “administer methotrexate (MTX) or thiotepa (for patients intolerant to MTX) combined with R-CHOP and orelabrutinib for six cycles, with each cycle lasting 21 days.” NCT06901999 ↗ “Cyclosporine A (CsA) + Mycophenolate mofetil dispersible tablets (MMF) + short-term low-dose methotrexate (MTX) + rabbit anti-human antithymocyte globulin (ATG)” NCT06816134 ↗ “Patients with stage I/II PTL who had not received treatment received 2 cycles of IV high-dose methotrexate (MTX) (1.5 g/m2) after 6 cycles of the R-CHOP regimen” PMID 38181782 ↗ Mar 2024 “Therefore, a parallel-group randomised controlled trial was designed to evaluate the efficacy and safety of MZWD combined with methotrexate (MTX) on early RA.” PMID 38238175 ↗ Jan 2024 “Methotrexate (MTX) is one of the critical components for treating all forms of acute lymphoblastic leukemia (ALL), which is the most common pediatric cancer.” NCT02011022 ↗ “comparing the efficacy, safety and cost-effectiveness of methotrexate (MTX), adalimumab (ADA), or their combination in non-infectious non-anterior uveitis.” NCT04798755 ↗ “Patients were treated with methotrexate (MTX), hydroxychloroquine (HCQ), oral Qingre Huoxue granule placebo and Qingre Huoxue external preparation placebo.” NCT02551575 ↗ “Patients will be randomised 1:1 to first-line ETN and methotrexate (MTX) or MTX with additional synthetic disease modifying anti-rheumatic drugs (sDMARDs)” PMID 26847108 ↗ Feb 2016 “MUSICA evaluated methotrexate (MTX) 20 mg/week versus 7.5 mg/week in combination with adalimumab (ADA) in RA patients with an inadequate response to MTX.” PMID 30173153 ↗ Sep 2018 “1. Oral methotrexate (MTX): The weekly dose will be 15 mg for children ≥ 40kg, 12.5 mg for children 30 to \<40 kg, and 10 mg for children 20 to \<30 kg.” NCT02772965 ↗ “PURPOSE: To confirm the feasibility and estimate the efficacy of methotrexate (MTX), teniposide, carmustine, and methylprednisolone (MBVP) chemotherapy” PMID 14597741 ↗ Nov 2003 “Eighteen patients with diffuse SSc of <or=5 years duration were randomized to receive rapamycin or methotrexate (MTX) in a single-blind, 48-week study.” PMID 19950289 ↗ Dec 2009 “To assess the indications, efficiency and tolerance profiles of methotrexate (MTX) in patients with giant cell arteritis (GCA) in a real-life setting.” PMID 36963127 ↗ Mar 2023 “Patients with CNS leukemia at presentation also receive methotrexate (MTX) intrathecally (IT) via an Ommaya reservoir weekly until the CSF is clear.” NCT00002514 ↗ “After confirming the diagnosis of tubal ectopic pregnancy, each patient received a single dose of intramuscular MTX (50 mg/m² MTX) on the same day.” NCT06504082 ↗ “Methotrexate (MTX) has remained the backbone of the treatment for moderate to severe psoriasis ever since its first use nearly half a century ago.” NCT06870500 ↗ “RCOG guidelines (No. 38February 2010 ) recommends the use of rescue regimen of alternating methotrexate( MTX) and leucoverin for 8 days (class D).” NCT03280979 ↗ “Methotrexate (MTX) has remained the backbone of the treatment for moderate to severe psoriasis ever since its first use nearly half a century ago.” NCT07086924 ↗ “A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)” NCT04762498 ↗ “OBJECTIVE: To determine if folinic acid supplementation during methotrexate (MTX) therapy for rheumatoid arthritis (RA) reduces both urinary” PMID 15476202 ↗ Oct 2004 “OBJECTIVE: To examine the effect of methotrexate (MTX) on pain and structural progression in symptomatic erosive hand osteoarthritis (HOA).” PMID 34157578 ↗ May 2021 “The study will investigate the safety and efficacy of combined methotrexate (MTX) + glucocorticoids (GC) treatment compared with GC alone.” NCT00651040 ↗ “The longest treatment phase in both protocols is maintenance therapy, which is composed of 6-Mercaptopurine (6MP) and Methotrexate (MTX).” NCT02912676 ↗ “Methotrexate (MTX) will be administered as concomitant medication in the dose escalation as well as in the randomized part of the study.” NCT02076659 ↗ “Topical minoxidil 5% gel and methotrexate (MTX) 1% gel are important modalities used in the treatment of many dermatological diseases.” PMID 35796224 ↗ Jul 2022 “CR6086 30 mg bid for 12 weeks as add-on to methotrexate (MTX) once weekly. MTX uptitrated to stable dosing as per standard guidelines” NCT03163966 ↗ “Patients with inflammatory bowel disease (IBD) who require methotrexate (MTX)for treatment currently receive this drug by injection.” NCT00035074 ↗ “The primary trial objective was to test if treatment with multi-day methotrexate (MTX) was inferior to pulse actinomycin-D (ACT-D).” PMID 32460997 ↗ May 2020 “Methotrexate (MTX) is an antifolate agent widely used for treating conditions such as rheumatoid arthritis and hematologic cancer.” PMID 38860384 ↗ Jun 2024 “Methotrexate(MTX) and/or 1 DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)” NCT01211834 ↗ “Methotrexate (MTX) remains the gold standard disease-modifying antirheumatic drug for the treatment of rheumatoid arthritis (RA).” PMID 24976447 ↗ Jun 2014 “Cyclosporine or tacrolimus(CNI)+Mycophenolate mofetil(MMF)± Short Course Methotrexate(MTX)+Anti-human T-lymphocyte Globulin（ATG）” NCT06949267 ↗ “Imatinib 400 mg Daily in Combination With Methotrexate (MTX)Compared to MTX Alone in the Treatment of Rheumatoid Arthritis (RA).” NCT00154336 ↗ “Methotrexate (MTX) is an anti-metabolite most commonly used in chemotherapy and immunosuppressant in auto-immune diseases.” NCT06231745 ↗ “using methotrexate (MTX) and the nucleoside analog fludarabine in 40 patients with severe refractory rheumatoid arthritis” NCT00001677 ↗ “Participants received methotrexate (MTX) orally once weekly with dose ranging from 10 to 20 mg per week through Week 52.” NCT01711359 ↗ “Methotrexate (MTX)3 g/m2,IV, d1 (24h)in consolidation, cycles 1 and 2 MTX (15 mg/m2/wk, IM)in maintenance MTX 15 mg, IT” NCT00853008 ↗ “combination etanercept and methotrexate (ETN + MTX) versus combination synthetic disease modifying antirheumatic drugs” PMID 23294908 ↗ Jan 2013 “Methotrexate (MTX) helps to decrease synovitis in many inflammatory joint diseases, particularly rheumatoid arthritis.” NCT01927484 ↗ “Intralesional methotrexate (MTX) could to be promising conservative alternative for non-melanoma skin cancer (NMSC).” NCT05315128 ↗ “initial dose of methotrexate for all patients will be 10 mg/week. 2)2 month: dose of MTX will remain at 10 mg/week” NCT00579644 ↗ “high-dose systemic methotrexate (MTX) and dexamethasone (DEX) combined with zidovudine (AZT) and brain irradiation” NCT00000723 ↗ “Participants also received methotrexate (MTX) 10 to 25 milligrams per week (mg/week), orally (PO) or parenterally” NCT00462345 ↗ “Can be FK506 (Tacrolimus/Prograf®), mycophenolate mofetil ((MMF)/Cellcept®), or methotrexate (MTX, amethopterin)” NCT01020539 ↗ “We performed a pharmacokinetic evaluation of methotrexate (MTX) in infants with acute lymphoblastic leukemia” PMID 17136402 ↗ Nov 2006 “peficitinib in combination with methotrexate (MTX) in patients with moderate-to-severe rheumatoid arthritis” PMID 27748083 ↗ Apr 2017 “Methotrexate (MTX): 1 g/m² IV over 24h (Day 1) with urine alkalinization (pH \>7.0) and leucovorin rescue.” NCT07059156 ↗ “A PHASE I/II STUDY OF RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH METHOTREXATE (MTX) AND CYCLOSPORINE (CPS)” NCT00002790 ↗ “Methotrexate (MTX) is an alternative treatment for patients with moderate/severe atopic dermatitis (AD).” PMID 37730501 ↗ Sep 2023 “associated with methotrexate (MTX) received either orally or subcutaneously at a dose of 12.5 mg / week” NCT02313870 ↗ “Throughout the study, both groups will continue the weekly self-administered subcutaneous MTX treatment” PMID 29703851 ↗ Apr 2018 “Tocilizumab (TCZ) and methotrexate (MTX) combination therapy 8mg/kg 4-weekly for a total of 48 weeks.” NCT04157010 ↗ “104 weeks of continuous oral low dose chemotherapy with cyclophosphamide (CPM) and methotrexate (MTX)” NCT03063983 ↗ “all received methotrexate (MTX), in addition to which 135 patients received oral GC bridging therapy” PMID 41943506 ↗ Apr 2026 “triple intrathecal (IT) chemotherapy comprising methotrexate (MTX), cytarabine, and hydrocortisone” NCT00084838 ↗ “Methotrexate (MTX) is a medication used to treat inflammation in people with rheumatoid arthritis.” NCT01949116 ↗ “High-dose methotrexate : 8-12 g/m2 (MTX chemotherapy requires blood drug concentration monitoring)” NCT05926492 ↗ “low-dose methotrexate (MTX), mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib.” NCT05132166 ↗ “methotrexate (MTX) intrathecally (IT), doxorubicin (DOX) IV, and hydrocortisone (HC) IT on day 1” NCT00006455 ↗ “clazakizumab in combination with methotrexate (MTX) or clazakizumab monotherapy versus MTX alone” PMID 26138593 ↗ Oct 2015 “Methotrexate (MTX) and hydrocortisone (HC) into the spinal fluid (IT), each age adjusted, day 1” NCT00187161 ↗ “include Cyclosporine (CsA),Methotrexate (MTX), Mycopherol ester (MMF) and Antithymic Globulin” NCT05149365 ↗ “Induction course 1: Methotrexate (MTX) Intrathecal therapy (IT) prophylaxis is age-adjusted.” NCT06262438 ↗ “Patients were treated with Methotrexate (MTX)and Tripterygium wilfordii Hook F（TwHF）placebo.” NCT03337815 ↗ “Received treatment with Methotrexate(MTX)for at least 24 weeks prior to the Baseline Visit.” NCT00993317 ↗ “We aimed to evaluate the ability of methotrexate (MTX) to decrease adalimumab immunisation.” PMID 31958280 ↗ Jan 2020 “Methotrexate (MTX) is widely used in the treatment of all inflammatory rheumatic diseases.” NCT04326894 ↗ “Use of low dose methotrexate (MTX) in psoriasis patients receiving an anti TNF alpha agent” NCT02829424 ↗ “BACKGROUND: Methotrexate (MTX) is a cornerstone in the treatment of rheumatoid arthritis.” PMID 22516039 ↗ Apr 2012 “methotrexate discontinuation group : stop MTX for 2 weeks after each shingrix vaccination” NCT06574594 ↗ “Methotrexate (MTX) to be administered once a week every week during the treatment period.” NCT02795299 ↗ “The aim of this study was to compare single dose Methotrexate (MTX) to multiple dose MTX.” NCT01662167 ↗ “Methotrexate (MTX) is a folic acid antagonist-an antiproliferative drug, as it is known.” NCT06641128 ↗ “prednisone (PDN) versus PDN plus methotrexate (MTX) versus PDN plus Cyclosporine A (CsA)” NCT00323960 ↗ “dose-limiting toxicity of methotrexate (MTX) when given in combination with glucarpidase” NCT00727831 ↗ “Methotrexate (MTX) was administered weekly according to the subject's pre-study MTX dose” NCT01661140 ↗ “Tocilizumab (TCZ) in Combination With Methotrexate (MTX) Versus Tocilizumab Monotherapy” NCT01587989 ↗ “short-term low-dose methotrexate (MTX) + rabbit anti-human antithymocyte globulin (ATG)” NCT07562568 ↗ “weekly subcutaneous abatacept+methotrexate (MTX) or abatacept placebo+MTX for 56 weeks.” PMID 36585217 ↗ Dec 2022 “DMARDs (methotrexate: MTX, leflunomide: LEF) were taken orally for at least 12 months.” NCT01600521 ↗ “Participants will continue taking their current Methotrexate (MTX) treatment regimen.” NCT01004432 ↗ “Rituximab, methotrexate (MTX), procarbazine, vincristine, and lenalidomide (RL-MPV).” NCT05425654 ↗ “Methotrexate (MTX) constitutes the first-line therapy in rheumatoid arthritis (RA)” PMID 32926395 ↗ Sep 2020 “Since methotrexate (mtx) and cyclo synergistically inhibit other disease processes” NCT00905073 ↗ “Patients receive methotrexate (MTX) IV over 2 hours once on weeks 1, 3, 5, and 7.” NCT00003632 ↗ “GSK2618960 2mg/kg will be administered intravenously (IV) with Methotrexate (MTX)” NCT03239600 ↗ “a stable dose of methotrexate (MTX) and tumor necrosis factor inhibitors (TNFi)” PMID 41703606 ↗ Feb 2026 “including cyclophosphamide(CYC), methotrexate(MTX) and azathioprine(AZA) etc.” NCT03096275 ↗ “Methotrexate (MTX) is widely used to control different types of inflammation.” NCT01633983 ↗ “in combination With Methotrexate (MTX) in Patients With Rheumatoid Arthritis” NCT01143337 ↗ “Methotrexate (MTX), mg 5 8 12 Ara-C, mg 16 20 30 Hydrocortisone,mg 10 10 20” NCT00526409 ↗ “Methotrexate (MTX), an anti-metabolite, has been in clinical use since 1948” NCT02644044 ↗ “QRHX granule 10g bid and methotrexate (MTX) 10 mg once a week for 24 weeks” NCT04170504 ↗ “High-dose intravenous (IV) pulse methotrexate (MTX) as a treatment for EF.” PMID 27541801 ↗ Nov 2016 “Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in” PMID 20574649 ↗ Jun 2010 “Methotrexate (MTX) is the first-line therapy for treatment of RA patients.” NCT05594680 ↗ “Methotrexate (MTX) is a chemotherapy agent and immune-system suppressant.” NCT06998628 ↗ “Maintenance therapy Methotrexate (MTX), 15 mg/m2/weekly intramuscularly.” NCT00482833 ↗ “Methotrexate (MTX) was supplied in tablet form, each of 2.5 mg strength.” NCT00487825 ↗ “Methotrexate (MTX) single oral dose of 3 × 2.5-mg tablet (Days 1 and 8)” NCT02456844 ↗ “methotrexate (MTX) is a potential, safer alternative to systemic route” PMID 42319271 ↗ Jun 2026 “Methotrexate (MTX), cytosine (ARA-C) and hydrocortisone, days 1 and 22” NCT00526175 ↗ “For subjects who are inadequate responders to methotrexate (MTX): MTX.” NCT03660059 ↗ “Methotrexate (MTX) in combination with infliximab was also tested.” PMID 18163509 ↗ Jan 2008 “methotrexate (MTX)and Tripterygium wilfordii Hook F（TwHF）placebo.” NCT03324412 ↗ “methotrexate (MTX) 10 mg/wk to 20 mg/wk, titrated over 2 months” NCT01164579 ↗ “Methotrexate, MTX, NSC-740; with Dipyridamole, DP, NSC-515776.” NCT00002487 ↗ “methotrexate (MTX) and prednisolone (PRDL) intrathecally (IT)” NCT00550992 ↗ “with or without Methotrexate (MTX), compared with MTX alone” NCT00361335 ↗ “one dose of methotrexate (MTX) intrathecally (IT) on day 1” NCT00613457 ↗ “one dose of methotrexate (MTX) intrathecally (IT) on day 1” NCT00430118 ↗ “Patients received either methotrexate (MTX) 0.5 mg/kg/week” PMID 22183975 ↗ Dec 2011 “after Methotrexate ( MTX). treatment for Ectopic pregnancy” NCT01860690 ↗ “All patients received a stable dose of methotrexate (MTX).” PMID 35250032 ↗ Mar 2022 “rituximab plus methotrexate (MTX) compared with MTX alone” PMID 21557525 ↗ May 2011 “findings with low-dose methotrexate (MTX) are encouraging” NCT02124226 ↗ “Participants will receive Methotrexate(MTX)+prednisolone.” NCT03775460 ↗ “one dose of methotrexate (MTX) intrathecal (IT) on day 1” NCT01117441 ↗ “both azathioprine (AZA) and methotrexate (MTX) are used.” NCT05040464 ↗ “background methotrexate (MTX) at baseline and 24 weeks.” PMID 24498318 ↗ Feb 2014 “in combination with Methotrexate (MTX) 10 to 25 mg/week” NCT01900431 ↗ “Abatacept (ABA) + Methotrexate (MTX), double-blind (DB)” NCT00095147 ↗ “Methotrexate (MTX): 3.5 g/m² IV over 3 hours, on Day 2” NCT06946407 ↗ “High-Dose Methotrexate (MTX) + Cytarabine] ± Rituximab” NCT06520163 ↗ “abatacept plus methotrexate (MTX)-treated patients” PMID 26063454 ↗ Jun 2015 “High-dose methotrexate (MTX) -based chemotherapy” PMID 17008697 ↗ Oct 2006 “combined with methotrexate (MTX, 10 mg per week)” PMID 39707138 ↗ Dec 2024 “ARM 1(Methotrexate(MTX) plus Sulfasalazine(SSZ))” NCT01659242 ↗ “stable oral methotrexate (MTX) dose (7.5-25 mg)” NCT01450982 ↗ “in combination therapy with methotrexate (MTX)” NCT01120366 ↗ “Arm A: Methotrexate (MTX) + Cytarabine (Ara-C)” NCT01011920 ↗ “methotrexate (MTX) IV over 24 hours on day 10” NCT00040690 ↗ “MTX as an antimetabolite and antifolate drug” NCT05300009 ↗ “including methotrexate (MTX) 5 g/m(2) x 4” PMID 10627444 ↗ Jan 2000 “methotrexate (MTX, on days +1, +3 and +6)” NCT03689465 ↗ “Cyclosporine (CSA) and methotrexate (MTX)” NCT00741455 ↗ “methotrexate (MTX) IT on day 1 of week 1” NCT00002531 ↗ “etanercept (ETN) plus methotrexate (MTX)” PMID 34496979 ↗ Sep 2021 “Methotrexate (Cy if no response to MTX)” NCT00003910 ↗ “single oral dose of methotrexate (MTX)” NCT03244462 ↗ “Placebo + methotrexate (MTX) (Group 1)” NCT01645280 ↗ “MTX 40 mg/m2 IM or IV; q (every) week;” NCT00187057 ↗ “in combination with methotrexate (MTX)” NCT02305849 ↗ “methotrexate (MTX) intrathecally (IT)” NCT00002700 ↗ “methotrexate (MTX)-naive RA patients” PMID 22127693 ↗ Dec 2011 “MTX (methotrexate) 40 mg/m2 IV or IM” NCT00187005 ↗ “tacrolimus (Tac), methotrexate (MTX)” NCT06315309 ↗ “methotrexate \[MTX\] 20 mg/m2 weekly” NCT02396043 ↗ “methotrexate (MTX) pharmacokinetics” NCT00847886 ↗ “Oral methotrexate (MTX) 15 mg/week” NCT00367237 ↗ “Methotrexate (MTX) 3.5g/m2 drip D1” NCT05347641 ↗ “Infliximab + methotrexate (MTX)” NCT00732875 ↗ “Tocilizumab + methotrexate(MTX)” NCT01258712 ↗ “golimumab + methotrexate (MTX)” NCT00973479 ↗ “methotrexate (MTX) monotherapy” PMID 22508468 ↗ Sep 2012 “Tocilizumab+Methotrexate(MTX)” NCT01347983 ↗ “including methotrexate (MTX).” PMID 21910713 ↗ Nov 2011 “MTX: Methotrexate,Leucovorin” NCT01083342 ↗ “Low-dose methotrexate (MTX)” NCT03112603 ↗ “Methotrexate, MTX, NSC-740” NCT00002476 ↗ “Methotrexate, MTX, NSC-740” NCT00002499 ↗ “MTX Methotrexate, NSC-740” NCT00002757 ↗ “MTX Methotrexate, NSC-740” NCT00002557 ↗ “MTX Methotrexate, NSC-740” NCT00002691 ↗ “Drug: Methotrexate (MTX)” NCT01116141 ↗ “Drug: Methotrexate (MTX)” NCT04772313 ↗ “Drug: Methotrexate (MTX)” NCT07352917 ↗ “Drug: Methotrexate (MTX)” NCT00547521 ↗ “Drug: methotrexate (MTX)” NCT02867306 ↗ “Drug: methotrexate (MTX)” NCT02814175 ↗ “Methotrexate (MTX)” NCT06590090 ↗ “Methotrexate (MTX)” NCT00803010 ↗ “methotrexate (MTX)” NCT00144521 ↗ “Methotrexate (MTX)” NCT06941376 ↗ “Methotrexate (MTX)” NCT06615050 ↗ “methotrexate (MTX)” NCT00002701 ↗ “methotrexate (MTX)” PMID 32611737 ↗ Jul 2020 “Methotrexate (MTX)” NCT06965244 ↗ “Methotrexate (MTX)” NCT02837146 ↗ “methotrexate (MTX)” NCT07185373 ↗ “Methotrexate (MTX)” NCT06252870 ↗ “Methotrexate (MTX)” NCT05135858 ↗ “Methotrexate (MTX)” NCT06541249 ↗ “Methotrexate (MTX)” NCT01909427 ↗ “Methotrexate (MTX)” NCT01248780 ↗ “methotrexate (MTX)” NCT00531817 ↗ “Methotrexate (MTX)” NCT07161336 ↗ “Methotrexate (MTX)” NCT03635957 ↗ “methotrexate (MTX)” NCT01217814 ↗ “Methotrexate (MTX)” NCT07381556 ↗ “Methotrexate (MTX)” NCT06973811 ↗ “Methotrexate (MTX)” NCT00658047 ↗ “Methotrexate (MTX)” NCT01855789 ↗ “Methotrexate (MTX)” NCT07280156 ↗ “Methotrexate (MTX)” NCT01737944 ↗ “Methotrexate (MTX)” NCT01745055 ↗ “Methotrexate (MTX)” NCT06913907 ↗ “Methotrexate (MTX)” NCT05036577 ↗ “Methotrexate（MTX）” NCT03522415 ↗ “MTX” NCT00221325 ↗ “MTX” NCT00045305 ↗ |
| Known as | MTX (methotrexate) | “MTX (methotrexate)” NCT00001880 ↗1“MTX (methotrexate)” NCT00602667 ↗ |
| Known as | MTX-LDE | “anti-inflammatory agent methotrexate in a cholesterol-rich non-protein nanoparticle (MTX-LDE)” NCT04616872 ↗1“Methotrexate carried by a lipid nanoparticle (MTX-LDE)” NCT04610567 ↗ |
| Known as | Novatrex | “Methotrexate (Novatrex ®) tablets 2.5 mg methotrexate 0.2 mg/kg/week as a single dose, orally for 8 weeks.” NCT01960283 ↗ |
| Known as | NSC-740 | “Iodine-131-labeled Monoclonal Antibody BC8 (anti-CD45), 131I-BC8; plus Busulfan, BU, NSC-750; Cyclophosphamide, CTX, NSC-26271; followed by Allogeneic Bone Marrow, ABM; with,...” NCT00002554 ↗5“Methotrexate, MTX, NSC-740; with Dipyridamole, DP, NSC-515776.” NCT00002487 ↗ “Methotrexate, MTX, NSC-740” NCT00002476 ↗ “Methotrexate, MTX, NSC-740” NCT00002499 ↗ “MTX Methotrexate, NSC-740” NCT00002557 ↗ “MTX Methotrexate, NSC-740” NCT00002691 ↗ |
| Known as | Rheumatrex and others | “methotrexate (Rheumatrex and others)” NCT00132691 ↗ |
| Known as | Trexall, TEVA Inc (brand of methotrexate) | “Trexall, TEVA Inc (brand of methotrexate)” NCT01594333 ↗ |
| Known as | V404 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02125266 ↗ |
| Action | Inhibit | “We hypothesize that the effect of methotrexate in the treatment of rheumatoid arthritis is due to the inhibition of aminoimidazole-carboxamide ribotide transformylase” NCT00000395 ↗ |
| Modality | Small molecule | “This medication is an antimetabolite and antifolate drug.” NCT01528163 ↗ |
| Route | Intravenous | “the sixth medicine (methotrexate) is given IV on day 15 of each cycle” NCT00000689 ↗ |
| Target | DHFR | “Methotrexate, an anti-metabolite drug which inhibits dihydrofolate reductase, is indicated in hematologic malignancies and in autoimmune diseases.” NCT01960283 ↗ |